OpRegen is a cell therapy commercialized by Lineage Cell Therapeutics, with a leading Phase II program in Geographic Atrophy. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of OpRegen’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for OpRegen is expected to reach an annual total of $19 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

OpRegen Overview

OpRegen is under development for the treatment of geographic atrophy, severe dry-form of age-related macular degeneration (AMD). The drug candidate is administered into the sub-retinal space during an intraocular injection. It is a suspension of retinal pigment epithelial (RPE) cells which are embryonic stem cell-derived RPE cells.

Lineage Cell Therapeutics Overview

Lineage Cell Therapeutics (Lineage) formerly known as BioTime, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. The company lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration, Opc1 in acute spinal cord injury, and Vac2 for non-small cell lung cancer. The company has subsidiaries in Israel, Singapore, and the US. Lineage is headquartered in Carlsbad, California, the US.

The company reported revenues of (US Dollars) US$4.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.8 million in FY2020. The operating loss of the company was US$48.7 million in FY2021, compared to an operating loss of US$26.5 million in FY2020. The net loss of the company was US$43 million in FY2021, compared to a net loss of US$20.7 million in FY2020. The company reported revenues of US$3 million for the third quarter ended September 2022, a decrease of 34.2% over the previous quarter.

For a complete picture of OpRegen’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.